Clinical Trial Update: A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating tOTX015 in combination with azacitidine or azacitidine alone in newly diagnosed acute myeloid leukemia patients not candidates for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• tOTX015

Snippet

Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN